Aspirin and clopidogrel resistance

Erin Donnelly Michos, Reza Ardehali, Roger S Blumenthal, Richard A. Lange, Hossein Ardehali

Research output: Contribution to journalArticle

Abstract

Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays. However, current clinical guidelines do not support routine screening for aspirin or clopidogrel resistance, in part because determination of the most appropriate screening test has not been established. This review attempts to (1) describe the phenomena of clinical aspirin and clopidogrel resistance (ie, treatment failure), (2) discuss the complexity of defining and identifying aspirin and clopidogrel resistance, (3) identify factors that may be responsible for aspirin and clopidogrel resistance, (4) outline several standard platelet function assays and their limitations, and (5) describe potential new antiplatelet therapies that may benefit aspirin- or clopidogrel-resistant patients.

Original languageEnglish (US)
Pages (from-to)518-526
Number of pages9
JournalMayo Clinic Proceedings
Volume81
Issue number4
DOIs
StatePublished - 2006

Fingerprint

clopidogrel
Aspirin
Blood Platelets
Treatment Failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aspirin and clopidogrel resistance. / Michos, Erin Donnelly; Ardehali, Reza; Blumenthal, Roger S; Lange, Richard A.; Ardehali, Hossein.

In: Mayo Clinic Proceedings, Vol. 81, No. 4, 2006, p. 518-526.

Research output: Contribution to journalArticle

Michos, ED, Ardehali, R, Blumenthal, RS, Lange, RA & Ardehali, H 2006, 'Aspirin and clopidogrel resistance', Mayo Clinic Proceedings, vol. 81, no. 4, pp. 518-526. https://doi.org/10.4065/81.4.518
Michos, Erin Donnelly ; Ardehali, Reza ; Blumenthal, Roger S ; Lange, Richard A. ; Ardehali, Hossein. / Aspirin and clopidogrel resistance. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 4. pp. 518-526.
@article{e161323e229c46b3a07fa0c83a1f353f,
title = "Aspirin and clopidogrel resistance",
abstract = "Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays. However, current clinical guidelines do not support routine screening for aspirin or clopidogrel resistance, in part because determination of the most appropriate screening test has not been established. This review attempts to (1) describe the phenomena of clinical aspirin and clopidogrel resistance (ie, treatment failure), (2) discuss the complexity of defining and identifying aspirin and clopidogrel resistance, (3) identify factors that may be responsible for aspirin and clopidogrel resistance, (4) outline several standard platelet function assays and their limitations, and (5) describe potential new antiplatelet therapies that may benefit aspirin- or clopidogrel-resistant patients.",
author = "Michos, {Erin Donnelly} and Reza Ardehali and Blumenthal, {Roger S} and Lange, {Richard A.} and Hossein Ardehali",
year = "2006",
doi = "10.4065/81.4.518",
language = "English (US)",
volume = "81",
pages = "518--526",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Aspirin and clopidogrel resistance

AU - Michos, Erin Donnelly

AU - Ardehali, Reza

AU - Blumenthal, Roger S

AU - Lange, Richard A.

AU - Ardehali, Hossein

PY - 2006

Y1 - 2006

N2 - Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays. However, current clinical guidelines do not support routine screening for aspirin or clopidogrel resistance, in part because determination of the most appropriate screening test has not been established. This review attempts to (1) describe the phenomena of clinical aspirin and clopidogrel resistance (ie, treatment failure), (2) discuss the complexity of defining and identifying aspirin and clopidogrel resistance, (3) identify factors that may be responsible for aspirin and clopidogrel resistance, (4) outline several standard platelet function assays and their limitations, and (5) describe potential new antiplatelet therapies that may benefit aspirin- or clopidogrel-resistant patients.

AB - Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays. However, current clinical guidelines do not support routine screening for aspirin or clopidogrel resistance, in part because determination of the most appropriate screening test has not been established. This review attempts to (1) describe the phenomena of clinical aspirin and clopidogrel resistance (ie, treatment failure), (2) discuss the complexity of defining and identifying aspirin and clopidogrel resistance, (3) identify factors that may be responsible for aspirin and clopidogrel resistance, (4) outline several standard platelet function assays and their limitations, and (5) describe potential new antiplatelet therapies that may benefit aspirin- or clopidogrel-resistant patients.

UR - http://www.scopus.com/inward/record.url?scp=33645688380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645688380&partnerID=8YFLogxK

U2 - 10.4065/81.4.518

DO - 10.4065/81.4.518

M3 - Article

C2 - 16610572

AN - SCOPUS:33645688380

VL - 81

SP - 518

EP - 526

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -